Mixed Aqueous Extract of Salvia Miltiorrhiza Reduces Blood Pressure through Inhibition of Vascular Remodelling and Oxidative Stress in Spontaneously Hypertensive Rats

Autor: Xi Qing Chai, Manli Li, Sheng Jun An, Xue Li, Zhan Jiao, Tie Mei Shao, Jun Qiu Fu, Jing Zhang, Pei Liu
Rok vydání: 2016
Předmět:
Male
0301 basic medicine
Physiology
Aorta
Thoracic
Blood Pressure
Salvia miltiorrhiza
Pharmacology
medicine.disease_cause
lcsh:Physiology
Rats
Sprague-Dawley
chemistry.chemical_compound
Malondialdehyde
Rats
Inbred SHR
Transforming growth factor β1
Thoracic aorta
lcsh:QD415-436
chemistry.chemical_classification
lcsh:QP1-981
Endothelin-1
Angiotensin II
NOX4
NADPH Oxidase 4
Hypertension
Systole
Vascular Remodeling
Collagen Type I
Smad7 Protein
Vascular remodelling in the embryo
lcsh:Biochemistry
Transforming Growth Factor beta1
03 medical and health sciences
medicine.artery
medicine
Animals
RNA
Messenger
Cell Proliferation
Aorta
Reactive oxygen species
Plant Extracts
Superoxide Dismutase
NADPH Oxidases
Water
Fibroblasts
Actins
Oxidative Stress
030104 developmental biology
chemistry
Protocatechuic aldehyde
Reactive Oxygen Species
Oxidative stress
Zdroj: Cellular Physiology and Biochemistry, Vol 40, Iss 1-2, Pp 347-360 (2016)
ISSN: 1421-9778
1015-8987
DOI: 10.1159/000452550
Popis: Background/Aims: Salvia miltiorrhiza (SM) contains four major aqueous active ingredients, which have been isolated, purified and identified as danshensu (DSS), salvianolic acid A (Sal-A), salvianolic acid B (Sal-B) and protocatechuic aldehyde (PAL), totally abbreviated as SABP. Although SM is often used to treat various cardiovascular diseases in traditional Chinese medicine, the efficacy and function of optimal compatibility ratio of SM's active ingredients (SABP) in the prevention and treatment of cardiovascular diseases remain uncertain. This study investigated antihypertensive effect and underlying mechanisms of SABP vs. SM lyophilized powder (SMLP) in spontaneously hypertensive rats (SHR) and to establish the ratio of the optimal compatibility of DSS, Sal-A, Sal-B and PAL in improving cardiovascular functions. Methods: The SHRs were treated with either SABP or SMLP and their systolic blood pressures (SBP) were monitored. The isolated thoracic aorta of SHRs was segregated for immunohistochemistry, Hematoxylin-Eosin stain and mRNA and protein expression of NOX4, TGF-β1, Col-I, ET-1, α-SMA and Smad7. Moreover, the adventitial fibroblasts (AFs) were isolated and cultured from SD rats' aorta and the reactive oxygen species (ROS) production was determined after SABP or SMLP treatment. Results: SABP, but not SMLP, significantly reduced SBP, which were accompanied by the inhibited morphological changes in the thoracic aorta and the reduced mRNA and protein expression of NOX4, TGF-β1, Col-I, ET-1 and α-SMA, but the increased Smad 7 expression in SHRs. Moreover, SABP also resulted in a decreased ROS production in AFs of SD rats. Conclusions: These results indicate that SABP, but not SMLP, treatment potently inhibits hypertension through improvements of vascular remodeling and oxidative stress. The present study provides new evidence that the efficacy and function from optimal compatibility ratio of SM active ingredients is much better than its lyophilized powder, which represents a strategy to develop SM's new beneficial effect in improving cardiovascular functions.
Databáze: OpenAIRE
Externí odkaz: